All In Biotech

Drug Trial Radar · NCT05073484

Assessment of Safety and Preliminary Efficacy With BAT6021 in Solid Tumor Patients

A Phase 1, Multi-Center, Open-Label Study to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BAT6021 as Mono Therapy or in Combination With BAT1308 in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

13

Actual

Start

Oct 29, 2021

Primary completion

Mar 30, 2023

Study completion Mar 30, 2023

Sponsor

Lead sponsor
Bio-Thera SolutionsIndustry
Sponsor type
Industry
First posted
Oct 11, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This first-in-human open-label, multi center, dose-escalation and expansion study is designed to evaluate the safety, tolerability, and PK of BAT6021 alone or in combination with BAT1308 (an anti-PD-1 antibody) in participants with locally advanced, recurrent, or metastatic incurable tumors for whom standard therapy does not exist, has proven to be ineffective or intolerable, or is considered inappropriate, or for whom a clinical trial of an investigational agent is a recognized standard of care.

Conditions

  • Advanced Solid Tumor

Interventions

  • BAT6021Drug

    Ⅳ infusions

  • BAT1308Drug

    Ⅳ infusions

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-limiting toxicity(DLT)Time frame: A minimum of 21 days after first dose of BAT6021
  2. Serious adverse event(SAE)Time frame: From the time of informed consent to 90 days after the last dose or until the initiation of a new cancer treatment.

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Liverpool Hospital

    Liverpool, New South Wales, Australia

  • Macquarie University Hospital

    Sydney, New South Wales, Australia

  • Cabrini Hospital Malvern

    Melbourne, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.